Galactosemic neuropathy in transgenic mice for human aldose reductase

被引:49
作者
Yagihashi, S
Yamagishi, SI
Wada, R
Sugimoto, K
Baba, M
Wong, HG
Fujimoto, J
Nishimura, C
Kokai, Y
机构
[1] HIROSAKI UNIV,SCH MED,DEPT NEUROL,HIROSAKI,AOMORI 036,JAPAN
[2] NATL CHILDRENS MED RES CTR,DEPT PATHOL,SETAGAYA KU,TOKYO 154,JAPAN
[3] NATL CHILDRENS MED RES CTR,DEPT PHARMACOL,SETAGAYA KU,TOKYO 154,JAPAN
关键词
D O I
10.2337/diabetes.45.1.56
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We studied the functional consequences of an enhanced polyol pathway activity, elicited with galactose feeding, on the peripheral nerve of transgenic mice expressing human aldose reductase, Nontransgenic littermate mice were used as controls. With a quantitative immunoassay, the expression level of human aldose reductase in the sciatic nerve was 791 +/- 44 ng/mg protein (mean +/- SE), about 25% of that in human sural nerve, When the transgenic mice were fed food containing 30% galactose, significant levels of galactitol accumulated in the sciatic nerve. Galactose feeding of nontransgenic littermate mice led to a 10-fold lower accumulation of galactitol, Galactose feeding for 16 weeks caused a significant and progressive decrease in motor nerve conduction velocity in transgenic mice to 80% of the level of galactose-fed littermate mice, which was not significantly different from that of galactose-free littermate mice. A morphometric analysis of sciatic nerve detected >10% reduction of mean myelinated fiber size but no alterations of myelinated fiber density in galactose-fed transgenic mice compared with other groups, The functional and structural changes that develop in galactose-fed transgenic mice are similar to those previously reported in diabetic animals. The results of these studies suggest that transgenic mice expressing human aldose reductase may be a useful model not only for defining the role of the polyol pathway in diabetic neuropathy but also for identifying and characterizing effective inhibitors specific for human aldose reductase.
引用
收藏
页码:56 / 59
页数:4
相关论文
共 40 条
[1]   ULTRASTRUCTURAL OBSERVATIONS ON MYELINATED FIBERS IN EXPERIMENTAL DIABETES - EFFECT OF THE ALDOSE REDUCTASE INHIBITOR PONALRESTAT GIVEN ALONE OR IN CONJUNCTION WITH INSULIN THERAPY [J].
BHOYRUL, S ;
SHARMA, AK ;
STRIBLING, D ;
MIRRLEES, DD ;
PETERSON, RG ;
FARBER, MO ;
THOMAS, PK .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1988, 85 (02) :131-147
[2]   COEXISTENCE OF NERVE-CONDUCTION DEFICIT WITH INCREASED NA+-K+-ATPASE ACTIVITY IN GALACTOSE-FED MICE - IMPLICATIONS FOR POLYOL PATHWAY AND DIABETIC NEUROPATHY [J].
CALCUTT, NA ;
TOMLINSON, DR ;
BISWAS, S .
DIABETES, 1990, 39 (06) :663-666
[3]   STATIL-SENSITIVE POLYOL FORMATION IN NERVE OF GALACTOSE-FED MICE [J].
CALCUTT, NA ;
WILLARS, GB ;
TOMLINSON, DR .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1988, 37 (05) :450-453
[4]   DIABETIC NEUROPATHY - NEW CONCEPTS OF ITS ETIOLOGY [J].
CLEMENTS, RS .
DIABETES, 1979, 28 (06) :604-611
[5]  
DVORNIK D, 1986, ALDOSE REDUCTASE INH
[6]  
DYCK PJ, 1993, PERIPHERAL NEUROPATH, P514
[7]   NERVE-CONDUCTION AND ALDOSE REDUCTASE INHIBITION DURING 5 YEARS OF DIABETES OR GALACTOSEMIA IN DOGS [J].
ENGERMAN, RL ;
KERN, TS ;
LARSON, ME .
DIABETOLOGIA, 1994, 37 (02) :141-144
[8]   ALDOSE REDUCTASE INHIBITION FAILS TO PREVENT RETINOPATHY IN DIABETIC AND GALACTOSEMIC DOGS [J].
ENGERMAN, RL ;
KERN, TS .
DIABETES, 1993, 42 (06) :820-825
[9]   CELLULAR PATHOLOGY OF THE NERVE MICROENVIRONMENT IN GALACTOSE INTOXICATION [J].
FORCIER, NJ ;
MIZISIN, AP ;
RIMMER, MA ;
POWELL, HC .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 1991, 50 (03) :235-255
[10]   THE ALDOSE REDUCTASE CONTROVERSY [J].
FRANK, RN .
DIABETES, 1994, 43 (02) :169-172